$TCRT

Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements wi

Alaunos Therapeutics (TCRT) raised $1.12M via a registered direct offering of 380,469 shares and pre-funded warrants at $1.46 per share. Proceeds will fund working capital and corporate purposes. The offering is expected to close on or around September 21, 2026. TCRT stock closed at $1.60 on Thursday, up 25.00%, and was at $1.44 in pre-market trading, down 8.13%.

Alaunos Therapeutics (TCRT) fell 16.81% to $1.3303 after announcing a $1.12M stock offering. The deal includes 380,469 shares and warrants at $1.46 per share, set to close by September 21, 2026. Proceeds will fund working capital. The stock's 52-week range is $1.27 to $4.59.

Alaunos Therapeutics Inc. (TCRT) stock surged 46.25% on optimism about its oncology pipeline. The company has minimal revenue, significant losses, and tight liquidity, making it a speculative play. TCRT's stock price is highly volatile, driven by trading flows rather than fundamentals, with intraday swings of over 50%. The company's financials show deep losses and negative returns, highlighting its speculative nature.

Alaunos Therapeutics (TCRT) shares rose 21.8% to $1.95 in pre-market trading after adopting new by-laws. Other stocks moving include CTNT (+77.8%), DLXY (+34.9%), GIPR (+29.5%), CPOP (+22.8%), BTCT (+12.9%), AMZE (+11.7%), SECZ (+8.6%), MASS (+7.7%), and HELP (+6.3%). Losers include XENE (-27.6%), DTSS (-16.4%), AIFF (-14.1%), ABTS (-13.5%), RENX (-13.3%), AGMH (-12.6%), WHLR (-11.2%), FRO (-6.4%), BHVN (-6.4%), and NUE (-3.1%).

Alaunos Therapeutics (NASDAQ:TCRT) shares rose 29.28% after hours following a SEC filing that showed the company adopted new bylaws, reducing the quorum required for shareholder meetings to one-third of outstanding voting shares. The change may facilitate future corporate actions. The stock has a market cap of $4.06M and traded between $1.28 and $4.59 over the past year.

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

Alaunos Therapeutics (NASDAQ: TCRT) has filed an amended annual report (10-K/A) to provide detailed information on its board structure, executive and director compensation, and significant shareholder ownership, which was initially omitted from its original 10-K filing. The amendment reaffirms a four-member board led by CEO Holger Weis and outlines various agreements, equity incentive plans, and audit fees, without altering previously reported financial statements. Key figures include a market value of non-affiliate holdings at $9.6 million and Robert W. Postma as the largest beneficial owner with 18.28% of shares.

Alaunos Therapeutics (NASDAQ:TCRT) has received a notice from Nasdaq for non-compliance with its listing rule requiring a minimum of $2.5 million in stockholders’ equity, as the company reported $2.153 million. The company must submit a compliance plan within 45 days and is exploring options to regain compliance, though there's no guarantee of acceptance or successful resolution. Non-compliance could lead to delisting, but Alaunos would have the right to appeal before a Nasdaq hearings panel.

Alaunos Therapeutics reported minimal revenue and a net loss for the year, primarily due to operating expenses. The company has pivoted its programs from oncology to an obesity/metabolic program, which has shown promising preclinical results. Future advancement of this program is contingent on securing additional capital and strategic partnerships.